FDA approves Replimune melanoma drug previously rejected twice Reversal, capping a tumultuous saga, is a big win for the biotech company, patient advocates

https://www.statnews.com/2026/08/06/replimune-melanoma-drug-rp1-fda-approves-phase-3-confirmatory-trial/ By Elaine ChenAug. 6, 2026 Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.